Literature DB >> 7713875

Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells.

M J Spinella1, K E Brigle, E E Sierra, I D Goldman.   

Abstract

L1210 leukemia cells transport reduced folates and methotrexate via a well defined reduced folate carrier system and, in the absence of low folate selective pressure, do not express an alternate endocytotic route mediated by cell surface folate receptors. This laboratory previously described an L1210 leukemia cell line, MTXrA, with acquired resistance to methotrexate (MTX) due to the loss of mobility of the reduced folate carrier. We now report on the transfection of MTXrA with a cDNA encoding the murine homolog of the human folate receptor isoform of KB cells to produce MTXrA-TF1, which constitutively expresses high levels of FR-alpha. MTXrA-TF1 and L1210 cells were utilized to compare transport of methotrexate mediated by FR-alpha and the reduced folate carrier, respectively. Methotrexate influx in the two lines was similar when the extracellular level was 0.1 microM, but as the methotrexate concentration increased, influx via the reduced folate carrier increased in comparison to influx mediated by FR-alpha. Transport kinetics indicated both a approximately 20-fold lower influx Kb and Vmax for MTXrA-TF1 as compared to L1210 cells. The two cell lines exhibited distinct influx properties. Methotrexate influx in MTXrA-TF1 was markedly inhibited by 50 nM folic acid and metabolic poisons. In L1210 cells, 1.0 microM folic acid did not affect MTX influx, and metabolic poisons either had no effect on or increased methotrexate influx. Removal of extracellular chloride markedly inhibited transport in MTXrA-TF1 but stimulated influx in L1210 cells. When the pH was decreased to 6.2, methotrexate influx was not altered in MTXrA-TF1 but was reduced in L1210 cells. Probenecid and sulfobromophthalein inhibit methotrexate influx in both L1210 and MTXrA-TF1 cell lines; however, inhibition in MTXrA-TF1 could be accounted for on the basis of inhibition of methotrexate binding to FR-alpha. The data indicate that the reduced folate carrier and FR-alpha function independently and exhibit distinct properties. FR-alpha expressed at sufficient levels can mediate influx of MTX and folates into cells at rates comparable to the reduced folate carrier and hence has pharmacologic and physiologic importance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7713875     DOI: 10.1074/jbc.270.14.7842

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Cellular transport of CI-980.

Authors:  K E Hook; S A Przybranowski; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Synthesis and Preclinical Evaluation of Folate-NOTA-Al(18)F for PET Imaging of Folate-Receptor-Positive Tumors.

Authors:  Qingshou Chen; Xiangjun Meng; Paul McQuade; Daniel Rubins; Shu-An Lin; Zhizhen Zeng; Hyking Haley; Patricia Miller; Dinko González Trotter; Philip S Low
Journal:  Mol Pharm       Date:  2016-04-18       Impact factor: 4.939

3.  Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting.

Authors:  Cristina Müller; Alexander Hohn; P August Schubiger; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

Review 4.  Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.

Authors:  Rongbao Zhao; Larry H Matherly; I David Goldman
Journal:  Expert Rev Mol Med       Date:  2009-01-28       Impact factor: 5.600

5.  Folic acid transport via high affinity carrier-mediated system in human retinoblastoma cells.

Authors:  Viral Kansara; Durga Paturi; Shuanghui Luo; Ripal Gaudana; Ashim K Mitra
Journal:  Int J Pharm       Date:  2007-12-23       Impact factor: 5.875

6.  Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Authors:  Benjamin Theobald; Kathy Bonness; Alla Musiyenko; Joel F Andrews; Gudrun Urban; Xizhong Huang; Nicholas M Dean; Richard E Honkanen
Journal:  Mol Cancer Res       Date:  2013-05-13       Impact factor: 5.852

Review 7.  Folate action in nervous system development and disease.

Authors:  Olga A Balashova; Olesya Visina; Laura N Borodinsky
Journal:  Dev Neurobiol       Date:  2018-02-06       Impact factor: 3.964

8.  Fabrication of methotrexate-loaded gold nanoconjugates and its enhanced anticancer activity in breast cancer.

Authors:  Ramesh Chaudhari; Pal Patel; Nikita Meghani; Simran Nasra; Ashutosh Kumar
Journal:  3 Biotech       Date:  2021-03-18       Impact factor: 2.406

Review 9.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

Review 10.  The Concept of Folic Acid in Health and Disease.

Authors:  Yulia Shulpekova; Vladimir Nechaev; Svetlana Kardasheva; Alla Sedova; Anastasia Kurbatova; Elena Bueverova; Arthur Kopylov; Kristina Malsagova; Jabulani Clement Dlamini; Vladimir Ivashkin
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.